Gary Giarratano joins Radient Pharmaceuticals
Takes position of director of North American sales and marketing
Armed with a successful track record in the IVD industry, Giarratano brings more than 20 years of healthcare, sales and marketing leadership experience to the California-based firm. He is recognised for his contributions in new market development for Carcinoembryonic Antigen (CEA), PSA and HPV and led sales for the first company to secure US FDA approval on each of these assays.
‘Gary thoroughly understands the intricacies of the IVD marketplace and has repeatedly successfully driven market share for various new test kit products. We expect him to do the same for Onko-Sure,’ said Douglas MacLellan, ceo of RPC.
You may also like
Manufacturing
FDA releases guidance to clarify guidelines for 'remanufacturing' devices that need maintenance or repair
The guidelines includes information on reusable product labelling, what it classifies as 'remanufacturing' and how companies can ensure products follow guidelines after multiple uses